Literature DB >> 27324386

Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.

Uday Yanamandra1, Kamal Kant Sahu1, Nidhi Jain1, Gaurav Prakash1, Uma Saikia2, Pankaj Malhotra3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27324386     DOI： 10.1007/s00277-016-2732-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Authors:  Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-03

2.  A True Mimicker to Plasmacytoma Clinically, Radiologically, and Pathologically - A Rare Case Report.

Authors:  Shino P Ashly; Anu C Thomas; Sajeev S Vadakkedam
Journal:  Asian J Neurosurg       Date:  2021-12-18

3.  Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Authors:  Waleed Sabry; Yue Wu; Shruthi Ganeshappa Kodad
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

4.  Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient.

Authors:  Rodrigo Diaz; Julan Amalaseelan; Louise Imlay-Gillespie
Journal:  BMJ Case Rep       Date:  2018-10-21

5.  Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.

Authors:  Lili Cheng; Qi Song; Mengke Liu; Yan Wang; Hongmei Yi; Ying Qian; Pengpeng Xu; Shu Cheng; Chaofu Wang; Li Wang; Weili Zhao
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.